In the first clinical trial of nicotinamide mononucleotide (NMN), researchers have found that the compound previously demonstrated to counteract aspects of aging and improve metabolic health in mice also has clinically relevant effects in people.
from Healthy Aging News -- ScienceDaily https://ift.tt/3nh9iIn
No comments:
Post a Comment